Wearable Pedometer for Ambulation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ambulation+1 More
Wearable Pedometer - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a patient wearable device measuring steps and ambulation sessions decreases hospital length of stay, time to first ambulation, time to first bowel movement, incidence of venous thromboembolism, and costs.

Eligible Conditions
  • Ambulation
  • Wearable Devices

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Up to 1 month

Up to 1 month
Hospital Length of Stay
Hospital length-of-stay index
Rate of venous thromboembolism
Time to first ambulation
Time to first bowel movement
Total hospitalization costs

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control
1 of 2
Pedometer
1 of 2

Active Control

Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Wearable Pedometer · No Placebo Group · N/A

Pedometer
Device
Experimental Group · 1 Intervention: Wearable Pedometer · Intervention Types: Device
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 month

Who is running the clinical trial?

University of FloridaLead Sponsor
1,237 Previous Clinical Trials
698,303 Total Patients Enrolled
Jennifer Fishe, MDPrincipal InvestigatorUniversity of Florida
1 Previous Clinical Trials
2,500 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patient is hospitalized and/or is able to ambulate and/or is able to perform activities as tolerated upon hospital admission.
You have a score of 1 or less in the Fall Predictive Analytics score category of \"low risk\".
Patient with a MFS of < or equal to 50.
You are admitted to UF Health Jacksonville 8N progressive inpatient unit.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Florida100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Florida100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%